Crossmark

Effect of Fibroblast Growth Factor (FGF) 19 and 21 on Hip Geometry and Strength in Post-menopausal Osteoporosis (PMO)

Published Online: 2024-09-28

Authors

Kim, EunJi

Moore, Amelia. E.

Dulnoan, Dwight

Hampson, Geeta https://orcid.org/0000-0001-8465-5247
Funding

Funding for this research was provided by:

Royal Osteoporosis Society (191)
License Information

Text and Data Mining valid from 2024-09-28

Version of Record valid from 2024-09-28
More Information

Article History

Received: 14 May 2024

Accepted: 5 September 2024

First Online: 28 September 2024

Declarations

:

: Eunji Kim, Amelia Elizabeth Moore, Dwight Dulnoan, Geeta n Hampson have no competing interests to declare.

: Ethical approval for the initial study was obtained from the South East London Research and Ethics Committee, UK. All patients gave informed consent and agreed that their aliquoted samples which were not used in the initial study could be stored and used in future ethically approved studies. Ethical approval for using the stored biological samples was obtained from the Human Research Authority (HRA) UK and the Health and Care Research Committee, Wales, UK. The current study was carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Document is current